Acquired resistance to drugs targeting receptor tyrosine kinases.

Development of resistance to chemotherapeutic drugs represents a significant hindrance to the effective treatment of cancer patients. The molecular mechanisms responsible have been investigated for over half a century and have revealed the lack of a single cause. Rather, a multitude of mechanisms have been delineated ranging from induction and expression of membrane transporters that pump drugs out of cells (multidrug resistance (MDR) phenotype), changes in the glutathione system and altered metabolism to name a few. Treatment of cancer patients/cancer cells with chemotherapeutic agents and/or molecularly targeted drugs is accompanied by acquisition of resistance to the treatment administered. Chemotherapeutic agent resistance was initially assumed to be due to induction of mutations leading to a resistant phenotype. This has also been true for molecularly targeted drugs. Considerable experience has been gained from the study of agents targeting the Bcr-Abl tyrosine kinase including imatinib, dasatinib and sunitinib. It is clear that mutations alone are not responsible for the many resistance mechanisms in play. Rather, additional mechanisms are involved, ranging from epigenetic changes, alternative splicing and the induction of alternative/compensatory signaling pathways. In this review, resistance to receptor tyrosine kinase inhibitors (RTKIs), RTK-directed antibodies and antibodies that inactivate ligands for RTKs are discussed. New approaches and concepts aimed at avoiding the generation of drug resistance will be examined. The recent observation that many RTKs, including the IGF-1R, are dependence receptors that induce apoptosis in a ligand-independent manner will be discussed and the implications this signaling paradigm has on therapeutic strategies will be considered.

[1]  D. Yee,et al.  Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins. , 2008, The Journal of clinical investigation.

[2]  A. Trumpp,et al.  Mechanisms of Disease: cancer stem cells—targeting the evil twin , 2008, Nature Clinical Practice Oncology.

[3]  William Pao,et al.  MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib , 2007, Proceedings of the National Academy of Sciences.

[4]  A. Lane,et al.  Histone deacetylase inhibitors in cancer therapy. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  N. Anderson,et al.  The Mitogenic Action of Insulin-like Growth Factor I in Normal Human Mammary Epithelial Cells Requires the Epidermal Growth Factor Receptor Tyrosine Kinase* , 2004, Journal of Biological Chemistry.

[6]  P. Zahradka,et al.  Tyrosine kinase-independent activation of extracellular-regulated kinase (ERK) 1/2 by the insulin-like growth factor-1 receptor. , 2011, Cellular signalling.

[7]  C. Arteaga,et al.  Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt Is required for antibody-mediated effects on p27, cyclin D1, and antitumor action. , 2002, Cancer research.

[8]  S. Keir,et al.  Combination testing (Stage 2) of the Anti‐IGF‐1 receptor antibody IMC‐A12 with rapamycin by the pediatric preclinical testing program , 2012, Pediatric blood & cancer.

[9]  C. Kahn,et al.  A Kinase-Independent Role for Unoccupied Insulin and IGF-1 Receptors in the Control of Apoptosis , 2010, Science Signaling.

[10]  Joon-Oh Park,et al.  MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling , 2007, Science.

[11]  P. Mehlen.  Dependence Receptors: The Trophic Theory Revisited , 2010, Science Signaling.

[12]  S. Rosenzweig,et al.  Paradoxical effects of the phage display-derived peptide antagonist IGF-F1-1 on insulin-like growth factor-1 receptor signaling. , 2006, Biochemical pharmacology.

[13]  Richard Gorlick,et al.  Initial testing (stage 1) of the IGF‐1 receptor inhibitor BMS‐754807 by the pediatric preclinical testing program , 2011, Pediatric blood & cancer.

[14]  H. Gronemeyer,et al.  Towards novel paradigms for cancer therapy , 2011, Oncogene.

[15]  P. Atadja,et al.  Effect of the histone deacetylase inhibitor LBH589 against epidermal growth factor receptor–dependent human lung cancer cells , 2007, Molecular Cancer Therapeutics.

[16]  R. Nahta,et al.  Herceptin: mechanisms of action and resistance. , 2006, Cancer letters.

[17]  Ben S. Wittner,et al.  A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations , 2010, Cell.

[18]  S. Goodin.  Erlotinib: Optimizing Therapy with Predictors of Response? , 2006, Clinical Cancer Research.

[19]  Patricia L. Harris,et al.  Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. , 2004, The New England journal of medicine.

[20]  J. Kuriyan,et al.  Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. , 2002, Cancer cell.

[21]  P. Seeburg,et al.  Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. , 2000, Science.

[22]  A. Berns,et al.  Drugging Drug Resistance , 2010, Cell.

[23]  Nathanael Gray,et al.  Factors underlying sensitivity of cancers to small-molecule kinase inhibitors , 2009, Nature Reviews Drug Discovery.

[24]  J. Fargnoli,et al.  Differential mechanisms of acquired resistance to insulin-like growth factor-i receptor antibody therapy or to a small-molecule inhibitor, BMS-754807, in a human rhabdomyosarcoma model. , 2010, Cancer research.

[25]  Donna Neuberg,et al.  Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. , 2005, Cancer cell.

[26]  S. Gabriel,et al.  EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy , 2004, Science.

[27]  Lesley Seymour,et al.  Erlotinib in lung cancer - molecular and clinical predictors of outcome. , 2005, The New England journal of medicine.

[28]  F. E. Bertrand,et al.  JAK/STAT, Raf/MEK/ERK, PI3K/Akt and BCR-ABL in cell cycle progression and leukemogenesis , 2004, Leukemia.

[29]  Brent M. Nowak,et al.  Evasion Mechanisms to Igf1r Inhibition in Rhabdomyosarcoma , 2011, Molecular Cancer Therapeutics.

[30]  J. Mestan,et al.  Identification of BCR-ABL point mutations conferring resistance to the Abl kinase inhibitor AMN107 (nilotinib) by a random mutagenesis study. , 2005, Blood.

[31]  K. Helin,et al.  Characterization of the retinoblastoma binding proteins RBP1 and RBP2. , 1993, Oncogene.

[32]  Ming Tan,et al.  PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. , 2004, Cancer cell.

[33]  W. McGuire,et al.  Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.

[34]  M. Clynes,et al.  Inhibition of IGF1R activity enhances response to trastuzumab in HER-2-positive breast cancer cells. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[35]  M. Deininger,et al.  Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia. , 2007, Blood.

[36]  T. Fleming,et al.  Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. , 2001, The New England journal of medicine.

[37]  M. Slomiany,et al.  Hypoxia-Inducible Factor-1-Dependent and -Independent Regulation of Insulin-Like Growth Factor-1-Stimulated Vascular Endothelial Growth Factor Secretion , 2006, Journal of Pharmacology and Experimental Therapeutics.

[38]  C. Sawyers,et al.  Comparative analysis of two clinically active BCR-ABL kinase inhibitors reveals the role of conformation-specific binding in resistance. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[39]  S. Ethier,et al.  EGFR/Met association regulates EGFR TKI resistance in breast cancer , 2010, Journal of molecular signaling.

[40]  Pixu Liu,et al.  Targeting the phosphoinositide 3-kinase pathway in cancer , 2009, Nature Reviews Drug Discovery.

[41]  Peter T. Yu,et al.  IGF1-R signals through the RON receptor to mediate pancreatic cancer cell migration. , 2011, Carcinogenesis.

[42]  P. Johnston,et al.  Chemotherapy-induced epidermal growth factor receptor activation determines response to combined gefitinib/chemotherapy treatment in non–small cell lung cancer cells , 2006, Molecular Cancer Therapeutics.

[43]  D. Gary Gilliland,et al.  The Retinoblastoma Binding Protein RBP2 Is an H3K4 Demethylase , 2007, Cell.

[44]  Ping Chen,et al.  Overriding Imatinib Resistance with a Novel ABL Kinase Inhibitor , 2004, Science.

[45]  R. Pestell,et al.  The type 1 insulin-like growth factor receptor and resistance to DACH1 , 2011, Cell cycle.

[46]  D. Dillon,et al.  IQGAP1 Protein Binds Human Epidermal Growth Factor Receptor 2 (HER2) and Modulates Trastuzumab Resistance* , 2011, The Journal of Biological Chemistry.

[47]  H. Varmus,et al.  Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain , 2005, PLoS medicine.

[48]  M. Meyerson,et al.  The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP , 2008, Proceedings of the National Academy of Sciences.

[49]  J. Mestan,et al.  In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. , 2005, Cancer research.

[50]  P. Mehlen,et al.  Dependence receptors: a new paradigm in cell signaling and cancer therapy , 2010, Oncogene.

[51]  Y. Lu,et al.  Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin). , 2001, Journal of the National Cancer Institute.

[52]  J. Melo,et al.  Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance. , 2000, Blood.

[53]  L. Helman,et al.  Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism , 2007, Oncogene.

[54]  H. Ji,et al.  Mechanistic insights into acquired drug resistance in epidermal growth factor receptor mutation‐targeted lung cancer therapy , 2010, Cancer science.

[55]  C. Pothoulakis,et al.  Insulin-like Growth Factor-1 Receptor Transactivation Modulates the Inflammatory and Proliferative Responses of Neurotensin in Human Colonic Epithelial Cells* , 2011, The Journal of Biological Chemistry.

[56]  Y. Yatabe,et al.  Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations. , 2008, Cancer research.

[57]  A. D. Van den Abbeele,et al.  Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[58]  E. Rozengurt,et al.  Crosstalk between Insulin/Insulin-like Growth Factor-1 Receptors and G Protein-Coupled Receptor Signaling Systems: A Novel Target for the Antidiabetic Drug Metformin in Pancreatic Cancer , 2010, Clinical Cancer Research.

[59]  L. VanWagner,et al.  Activation of the Insulin-like Growth Factor-1 Receptor Induces Resistance to Epidermal Growth Factor Receptor Antagonism in Head and Neck Squamous Carcinoma Cells , 2011, Molecular Cancer Therapeutics.

[60]  B. Druker,et al.  Oncogenes and Tumor Suppressors (795 articles) , 2004 .

[61]  R. Wilson,et al.  EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[62]  Jessica E. Bolden,et al.  Anticancer activities of histone deacetylase inhibitors , 2006, Nature Reviews Drug Discovery.

[63]  H. Atreya,et al.  Defining the pathway to insulin-like growth factor system targeting in cancer. , 2010, Biochemical pharmacology.

[64]  Yi Shen,et al.  Trastuzumab Regulates IGFBP-2 and IGFBP-3 to Mediate Growth Inhibition: Implications for the Development of Predictive Biomarkers for Trastuzumab Resistance , 2011, Molecular Cancer Therapeutics.

[65]  M. Slomiany,et al.  Insulin-like growth factor-1 receptor and ligand targeting in head and neck squamous cell carcinoma. , 2007, Cancer letters.